Positive Early Results Propel Amgen to Compete in Lucrative Weight-Loss Market
Amgen (AMGN) experienced a significant surge in its shares following encouraging remarks from its CEO, Robert Bradway, regarding early results from the study of the company’s experimental obesity drug, MariTide. Bradway expressed confidence in MariTide’s potential to address crucial unmet medical needs in the field of obesity treatment, triggering a notable uptick in investor optimism.
The California-based biopharmaceutical company’s stock soared by as much as 15% in pre-market trading, positioning it for its most significant increase since July 2009. Amgen is now emerging as a formidable competitor to industry giants like Eli Lilly & Co. and Novo Nordisk A/S in the weight-loss market. This move comes amidst a surge in demand for anti-obesity drugs, with projected annual sales expected to reach $80 billion by 2030.
Analysts are optimistic about MariTide’s potential, with William Blair analyst Matt Phipps highlighting its multi-blockbuster prospects. The drug’s differentiated profile, coupled with Amgen’s expertise, has bolstered confidence in its development.
Meanwhile, Denmark’s Novo Nordisk saw a decline in its shares following the Amgen CEO’s remarks, underlining the shifting dynamics in the competitive landscape. Amgen’s MariTide, with its novel approach and promising early-stage results, has ignited enthusiasm among investors and positioned the company for a significant role in the evolving obesity treatment market.
You might like this article: Moderna Reports Narrower Loss Amid Decline in Covid Vaccine Sales
